Echocardiography and Cardio-Oncology

Negishi, Tomoko; Miyazaki, Sakiko; Negishi, Kazuaki

doi:10.1016/j.hlc.2019.04.023

Cited by 13 publications

(12 citation statements)

References 40 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The new sub-specialty of cardio-oncology displays this broad spectrum of relevant application. Negishi and colleagues highlight that the emergence of cardio-oncology is a result of the paradigm shift from considering cancer as a ''terminal illness" to a ''chronic condition"-and, one with cardiovascular risks [22]. Cardio-oncology focusses on the risk stratification, prevention, early identification and treatment of cardiovascular complications related to cancer therapy.…”

mentioning

confidence: 99%

Echocardiography: Navigating Complexities to Provide Many Useful Applications in Contemporary Clinical Cardiology

Gregory

Stanton

Thomas

et al. 2019

Heart, Lung and Circulation

View full text Add to dashboard Cite

Echocardiography has been around for more than half a century [1]. Recent decades have seen significant technological advances, with increasing clinical applications of this non-invasive imaging tool, beyond the basic assessment of left ventricular function, with further evolution evident on the horizon. There has also been a burgeoning increase in use: According to the 2017 Australian Medicare Medical Benefits Schedule (MBS) Taskforce, about 900,000 echocardiographic procedures (excluding stress echo) are reimbursed annually, at a cost of over $180 million each year [2]. In addition, the use of echo is growing at a rate of about 8.8% each year [3]. Stress echocardiography accounts for over $56 million in billing annually in Australia and has grown each year at a rate of 12% for the past 5 years [4]. In recognition of this expanding use, this fully commissioned Special Issue of Heart, Lung and Circulation presents an overview of contemporary practice in echocardiography.

show abstract

mentioning

confidence: 99%

Echocardiography: Navigating Complexities to Provide Many Useful Applications in Contemporary Clinical Cardiology

Gregory

Stanton

Thomas

et al. 2019

Heart, Lung and Circulation

View full text Add to dashboard Cite

show abstract

“…Improved breast cancer survival together with better awareness of the later-stage effects of cardiotoxicity has led to growing recognition for surveillance of ANT-treated cancer survivors with early intervention to treat or prevent heart failure (30). Echocardiography is the most frequently used method to detect cardiac injury in breast cancer patients (31). Our study revealed that for breast cancer patients, LVEF values decreased after 6 months of ANT chemotherapy with no significant difference between post-and pre-chemotherapy.…”

Section: Discussionmentioning

confidence: 56%

Effects of the Chinese herbal medicine Hong Huang decoction, on myocardial injury in breast cancer patients who underwent anthracycline-based chemotherapy

Cao

Xue

Chen

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectiveTo assess the effects of Hong Huang Decoction (HHD), a Chinese herbal medicine, on myocardial injury in breast cancer patients who underwent anthracycline (ANT)-based chemotherapy.MethodsA total of 51 patients with breast cancer who underwent an ANT-based chemotherapy program and met the inclusion/exclusion criteria were allocated to the treatment or placebo groups using a random number generation process. Patients in the treatment group received liquid HHD twice a day. Treatment was given from 1 day prior to chemotherapy up to the end of chemotherapy (after 6 months). Participants in the placebo group received a placebo over the same schedule. Left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), diagnostic markers of acute myocardial infarction [e.g., lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP)], nitric oxide (NO), superoxide dismutase (SOD), as well as pro-inflammatory cytokines [e.g., tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and human C-reactive protein (CRP)], and anti-inflammatory cytokine interleukin-10 (IL-10), were outcome measures assessed before chemotherapy, 3 and 6 months after chemotherapy.ResultsCompared to the placebo group, the GLS value was significantly higher in the treatment group (19.95 ± 1.16 vs. 19.06 ± 1.64, P ≤ 0.001). Significant differences were also noted for levels of SOD (689.71 ± 203.60 vs. 807.88 ± 182.10, P < 0.05), IL-6 (58.04 ± 22.06 vs. 194.20 ± 40.14, P ≤ 0.001), IL-10 (237.90 ± 94.98 vs. 68.81 ± 32.92, P ≤ 0.001), NO (75.05 ± 26.39 vs. 55.83 ± 19.37, P ≤ 0.005), and TNF-α (301.80 ± 134.20 vs. 680.30 ± 199.60, P ≤ 0.001) in the patients before chemotherapy compared to 6 months after initiating chemotherapy.ConclusionHHD regulated the levels of IL-6, IL-10, SOD, NO, and TNF-α. The results demonstrated that GLS is a better indicator of early myocardial injury compared to LVEF, and HHD could modulate oxidative stress to protect against ANT cardio toxicity.Clinical trial registrationChinese Clinical Trial Registry, identifier ChiCTR1900022394. Date of registration: 2019-04-09.

show abstract

“…According to the 2022 ESC Guidelines on Cardio‐oncology, the Heart Failure Association‐International Cardio‐Oncology Society (HFA‐ICOS) risk assessment tool should be considered for the pre‐treatment screening 11 . Risk factors in cardio‐oncology can be divided into four groups: existing myocardial disease, cardiac risk factors, risk factors related to lifestyle and previous cardiotoxic cancer therapy 41 . After the identification of existing risk factors, a screening scheme should be planned.…”

Section: Pre‐treatment Screening Methodsmentioning

confidence: 99%

“…Negishi et al proposed a strategy that consists of imaging before treatment to evaluate risk factors and assess the indications for primary cardioprotective therapy and follow‐up imaging during therapy for the early detection of subclinical changes in myocardial systolic function. After‐treatment, imaging is recommended beginning 6–12 months after completion of the therapy in asymptomatic patients 41 . Following the expert consensus of the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE), asymptomatic patients without risk factors should be examined 10 years after RT.…”

Section: Pre‐treatment Screening Methodsmentioning

confidence: 99%

Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies

Bychowski

Sobiczewski

2023

Cancer Medicine

View full text Add to dashboard Cite

The cancer mortality rate has been declining over the past several decades due to the early detection, improved diagnosis and implementation of evidence-based practices. 1 In a GLOBOCAN study performed to estimate the worldwide incidence and mortality of the most prevalent cancers, the estimated mortality rate from lung cancer decreased from 36.8% in men in 2012 to 18% in 2020. In similar time, the mortality rate from breast cancer in women was reduced from 14.9% to 6.9%. 2,3 In 2016, the Polish Central Statistical Office reported 160,000 new cases of cancer in Poland. 4 More than half of this group will pass through oncological therapy. 5 Alongside this therapeutic success, there is an increasing population of cancer survivors at a higher risk of cardiovascular diseases (CVDs). Although the leading

show abstract

Echocardiography and Cardio-Oncology

Cited by 13 publications

References 40 publications

Echocardiography: Navigating Complexities to Provide Many Useful Applications in Contemporary Clinical Cardiology

Echocardiography: Navigating Complexities to Provide Many Useful Applications in Contemporary Clinical Cardiology

Effects of the Chinese herbal medicine Hong Huang decoction, on myocardial injury in breast cancer patients who underwent anthracycline-based chemotherapy

Current perspectives of cardio‐oncology: Epidemiology, adverse effects, pre‐treatment screening and prevention strategies

Contact Info

Product

Resources

About